Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity

Journal of Virology

Volumn 84, Issue 5, 2010, Pages 2408-2420

  Nayak, Baibaswata ^a   Kumar, Sachin ^a   DiNapoli, Joshua M ^b   Paldurai, Anandan ^a   Perez, Daniel R ^a   Collins, Peter L ^b   Samal, Siba K ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PROTEIN M2; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; AVIAN INFLUENZA; CHICKEN; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; GENE EXPRESSION; IMMUNITY; IMMUNIZATION; INFLUENZA VIRUS A H5N1; MORBIDITY; MORTALITY; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, NEUTRALIZING; CHICKENS; HEMAGGLUTININS, VIRAL; HUMANS; IMMUNITY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; NEWCASTLE DISEASE VIRUS; SURVIVAL RATE; VIRAL MATRIX PROTEINS; VIRAL PROTEINS; VIRUS SHEDDING;

AVES; AVIAN INFLUENZA VIRUS; GALLUS GALLUS; NEWCASTLE DISEASE VIRUS;

EID: 77649205430     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02135-09     Document Type: Article

References (45)

1. Alexander, D. J. 2007. An overview of the epidemiology of avian influenza. Vaccine 25:5637-5644.
2. Chen, Q., H. Kuang, H. Wang, F. Fang, Z. Yang, Z. Zhang, X. Zhang, and Z. Chen. 2009. Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 38:30-38.
3. Chen, Z., Y. Sahashi, K. Matsuo, H. Asanuma, H. Takahashi, T. Iwasaki, Y. Suzuki, C. Aizawa, T. Kurata, and S. Tamura. 1998. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 16:1544-1549.
4. Cleverley, D. Z., H. M. Geller, and J. Lenard. 1997. Characterization of cholesterol-free insect cells infectible by baculoviruses: effects of cholesterol on VSV fusion and infectivity and on cytotoxicity induced by influenza M2 protein. Exp. Cell Res. 233:288-296.
5. Denis, J., E. Acosta-Ramirez, Y. Zhao, M. E. Hamelin, I. Koukavica, M. Baz, Y. Abed, C. Savard, C. Pare, C. Lopez Macias, G. Boivin, and D. Leclerc. 2008. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 26:3395-3403.
6. DiNapoli, J. M., L. Yang, A. Suguitan, Jr., S. Elankumaran, D. W. Dorward, B. R. Murphy, S. K. Samal, P. L. Collins, and A. Bukreyev. 2007. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J. Virol. 81:11560-11568.
7. Fan, J., X. Liang, M. S. Horton, H. C. Perry, M. P. Citron, G. J. Heidecker, T. M. Fu, J. Joyce, C. T. Przysiecki, P. M. Keller, V. M. Garsky, R. Ionescu, Y. Rippeon, L. Shi, M. A. Chastain, J. H. Condra, M. E. Davies, J. Liao, E. A. Emini, and J. W. Shiver. 2004. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22:2993-3003.
8. Fiers, W., M. De Filette, A. Birkett, S. Neirynck, and W. Min Jou. 2004. A "universal" human influenza A vaccine. Virus Res. 103:173-176.
9. Fouchier, R. A., V. Munster, A. Wallensten, T. M. Bestebroer, S. Herfst, D. Smith, G. F. Rimmelzwaan, B. Olsen, and A. D. Osterhaus. 2005. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79:2814-2822.
10. Frace, A. M., A. I. Klimov, T. Rowe, R. A. Black, and J. M. Katz. 1999. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17:2237-2244.
11. Ge, J., G. Deng, Z. Wen, G. Tian, Y. Wang, J. Shi, X. Wang, Y. Li, S. Hu, Y. Jiang, C. Yang, K. Yu, Z. Bu, and H. Chen. 2007. Newcastle disease virusbased live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J. Virol. 81:150-158.
12. Heinen, P. P., F. A. Rijsewijk, E. A. de Boer-Luijtze, and A. T. Bianchi. 2002. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J. Gen. Virol. 83:1851-1859.
13. Hierholzer, J. C., and R. A. Killington. 1996. Virus isolation and quantitation, p. 25-46. In B. W. Mahy and H. I. Kangro (ed.), Virology methods manual. Academic Press, London, United Kingdom.
14. Huang, Z., S. Krishnamurthy, A. Panda, and S. K. Samal. 2001. High-level expression of a foreign gene from the most 3′-proximal locus of a recombinant Newcastle disease virus. J. Gen. Virol. 82:1729-1736.
15. Huang, Z., A. Panda, S. Elankumaran, D. Govindarajan, D. D. Rockemann, and S. K. Samal. 2004. The hemagglutinin-neuraminidase protein of Newcastle disease virus determines tropism and virulence. J. Virol. 78:4176-4184.
16. Ilyinskii, P. O., V. L. Gabai, S. R. Sunyaev, G. Thoidis, and A. M. Shneider. 2007. Toxicity of influenza A virus matrix protein 2 for mammalian cells is associated with its intrinsic proton-channeling activity. Cell Cycle 6:2043-2047.
17. Ilyinskii, P. O., A. S. Gambaryan, A. B. Meriin, V. Gabai, A. Kartashov, G. Thoidis, and A. M. Shneider. 2008. Inhibition of influenza M2-induced cell death alleviates its negative contribution to vaccination efficiency. PLoS One 3:e1417.
18. Jegerlehner, A., N. Schmitz, T. Storni, and M. F. Bachmann. 2004. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172:5598-5605.
19. Johansson, B. E., and I. C. Brett. 2008. Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines. Hum. Vaccin. 4:420-424.
20. Johansson, B. E., B. Grajower, and E. D. Kilbourne. 1993. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 11:1037-1039.
21. Kolakofsky, D., T. Pelet, D. Garcin, S. Hausmann, J. Curran, and L. Roux. 1998. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J. Virol. 72:891-899.
22. Kretzschmar, E., L. Buonocore, M. J. Schnell, and J. K. Rose. 1997. Highefficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J. Virol. 71:5982-5989.
23. Liu, W., P. Zou, and Y. H. Chen. 2004. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol. Lett. 93:131-136.
24. McNulty, M. S., G. M. Allan, and B. M. Adair. 1986. Efficacy of avian influenza neuraminidase-specific vaccines in chickens. Avian Pathol. 15:107-115.
25. Nayak, B., S. N. Rout, S. Kumar, M. S. Khalil, M. M. Fouda, L. E. Ahmed, K. C. Earhart, D. R. Perez, P. L. Collins, and S. K. Samal. 2009. Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS One 4:e6509.
26. Neirynck, S., T. Deroo, X. Saelens, P. Vanlandschoot, W. M. Jou, and W. Fiers. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5:1157-1163.
27. OIE. 2009. Facts & figures: avian influenza. 62 countries report H5N1 avian influenza in domestic poultry/wildlife 2003-2009. World Organisation for Animal Health, Paris, France. http://www.oie.int/eng/info-ev/ en-AI-factoids-2.htm.
28. OIE. 2009. Chapter 2.3.4. Avian influenza. Version adopted by the World Assembly of Delegates of the OIE in May 2009. In OIE terrestrial manual 2009. World Organisation for Animal Health, Paris, France. http://www.oie.int/eng/normes/mmanual/2008/pdf/2.03.04-AI.pdf.
29. OIE. 2004. Chapter 2.1.15. Newcastle disease. In Manual of diagnostic tests and vaccines for terrestrial animals. World Organisation for Animal Health, Paris, France. http://www.oie.int/fr/normes/mmanual/A-00038.htm.
30. OIE. 2009. Chapter 2.3.14. Newcastle disease. In OIE terrestrial manual 2009. World Organisation for Animal Health, Paris, France. http://www.oie .int/fr/normes/mmanual/2008/pdf/2.03.14-NEWCASTLE-DIS.pdf.
31. OIE/FAO/IZSVe. 2007. Avian influenza vaccination: OIE information document-Verona recommendations. In Vaccination: a tool for the control of avian influenza. OIE/FAO/IZSVe Scientific Conference, Verona, Italy, 20 to 22 March 2007. http://www.oie.int/ENG/info-ev/Other%20Files/A- Guidelines%20on%20AI%20vaccination.pdf.
32. Park, M. S., J. Steel, A. Garcia-Sastre, D. Swayne, and P. Palese. 2006. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc. Natl. Acad. Sci. U. S. A. 103:8203-8208.
33. Pavlova, S. P., J. Veits, G. M. Keil, T. C. Mettenleiter, and W. Fuchs. 2009. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase. Vaccine 27:773-785.
34. Qiao, C., Y. Jiang, G. Tian, X. Wang, C. Li, X. Xin, H. Chen, and K. Yu. 2009. Recombinant fowlpox virus vector-based vaccine completely protects chickens from H5N1 avian influenza virus. Antiviral Res. 81:234-238.
35. Römer-Oberdörfer, A., J. Veits, D. Helferich, and T. C. Mettenleiter. 2008. Level of protection of chickens against highly pathogenic H5 avian influenza virus with Newcastle disease virus based live attenuated vector vaccine depends on homology of H5 sequence between vaccine and challenge virus. Vaccine 26:2307-2313.
36. Rout, S. N., and S. K. Samal. 2008. The large polymerase protein is associated with the virulence of Newcastle disease virus. J. Virol. 82:7828-7836.
37. Sandbulte, M. R., G. S. Jimenez, A. C. Boon, L. R. Smith, J. J. Treanor, and R. J. Webby. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4:e59.
38. Song, H., G. R. Nieto, and D. R. Perez. 2007. A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates. J. Virol. 81:9238-9248.
39. Subbarao, K., B. R. Murphy, and A. S. Fauci. 2006. Development of effective vaccines against pandemic influenza. Immunity 24:5-9.
40. Sylte, M. J., B. Hubby, and D. L. Suarez. 2007. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 25:3763-3772.
41. Treanor, J. J., E. L. Tierney, S. L. Zebedee, R. A. Lamb, and B. R. Murphy. 1990. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 64:1375-1377.
42. Veits, J., D. Wiesner, W. Fuchs, B. Hoffmann, H. Granzow, E. Starick, E. Mundt, H. Schirrmeier, T. Mebatsion, T. C. Mettenleiter, and A. Romer-Oberdorfer. 2006. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc. Natl. Acad. Sci. U. S. A. 103:8197-8202.
43. Webster, R. G., W. J. Bean, O. T. Gorman, T. M. Chambers, and Y. Kawaoka. 1992. Evolution and ecology of influenza A viruses. Microbiol. Rev. 56:152-179.
44. Webster, R. G., P. A. Reay, and W. G. Laver. 1988. Protection against lethal influenza with neuraminidase. Virology 164:230-237.
45. World Health Organization. 9 February 2009, posting date. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/ disease/avian-influenza/country/cases-table-2009-02-09/en/index.html.